There are lots of mistakes that corporate executives can make. One of the most problematic is overpromising and underdelivering. This blunder can lead to an erosion of credibility. Novavax (NASDAQ: NVAX) CEO Stan Erck and his leadership team face this very issue right now.
The company has maintained for a while now that it planned to file for U.S. Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate NVX-CoV2373 in the third quarter of 2021. However, Novavax announced last Thursday in its second-quarter update that its EUA submission in the U.S. will be pushed back into Q4.
The vaccine stock sank on Friday following the news. Is Novavax still a buy with its management's credibility crumbling?
For further details see:
Is Novavax Stock Still a Buy With Its Management's Credibility Crumbling?